Masimo (NASDAQ: MASI) has recently completed the sale of its sound united consumer audio business to Harman International, a wholly-owned subsidiary of Samsung Electronics Co., Ltd. This move is part of Masimo's strategy to focus on its core professional healthcare business and to prioritize share repurchases with the proceeds from the transaction.
The completion of the sound united sale marks an important milestone for Masimo, as it positions the company to broaden its patient impact, accelerate growth, and deliver stronger margins. Katie Szyman, the Chief Executive Officer of Masimo, expressed confidence in the company's ability to capitalize on exciting opportunities ahead and to continue building on its positive momentum to deliver value for all stakeholders.
In terms of financial advisors, Centerview Partners LLC and Morgan Stanley & Co. LLC served as financial advisors to Masimo, while Sullivan & Cromwell LLP served as the legal advisor in connection with the transaction.
Masimo (NASDAQ: MASI) is a global medical technology company known for developing and producing a range of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, automation, and connectivity solutions. Masimo's SET® measure-through motion and low perfusion™ pulse oximetry, introduced in 1995, has been demonstrated to outperform other pulse oximetry technologies in over 100 independent and objective studies. It is estimated to be used on more than 200 million patients around the world each year and is the primary pulse oximetry at all 10 top U.S. hospitals as ranked in the 2025 Newsweek World's Best Hospitals listing. Following these announcements, the company's shares moved -0.84%, and are now trading at a price of $140.93. Check out the company's full 8-K submission here.
